Keywords: new, study, confirms, zomig, long-term, safety, astrazeneca

New study confirms Zomig long-term safety

Article | 31 January 2005

Print This

AstraZeneca's Zomig (zolmitriptan) nasal spray is well-tolerated for the treatment of migraine during long-term use of up to one year, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in